Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| INSM - Insmed | 16.61% | Reduce −51.6% | 2,138,963 | $67.00 | $143M | −2,284,406 | +$23M |
| BMRN - Biomarin Pharmaceutical | 10.78% | Reduce −0.4% | 1,130,167 | $82.33 | $93M | −4,402 | −$6M |
| FOLD - Amicus | 10.38% | Reduce −3.4% | 9,029,843 | $9.92 | $90M | −314,259 | −$20M |
| UTHR - United Therapeutics | 9.85% | Reduce −0.3% | 266,914 | $318.55 | $85M | −845 | +$24M |
| BIIB - Biogen | 7.76% | Reduce −0.3% | 289,050 | $231.82 | $67M | −908 | +$4M |
| Staar Surgical | 7.62% | Add +0.1% | 1,381,619 | $47.61 | $66M | +2,029 | +$13M |
| ALNY - Alnylam Pharmaceuticals | 5.16% | New | 183,123 | $243.00 | $44M | +183,123 | +$44M |
| ACAD - Acadia Pharmaceuticals | 4.55% | Add +0.2% | 2,418,841 | $16.25 | $39M | +3,898 | −$5M |
| PRTA - Prothena | 3.99% | Add +0.2% | 1,666,378 | $20.64 | $34M | +2,930 | −$7M |
| Sarepta Therapeutics | 3.69% | Add +0.2% | 201,683 | $158.00 | $32M | +418 | +$6M |
| ANAB - Anaptysbio | 2.33% | Add +0.5% | 803,641 | $25.06 | $20M | +3,735 | +$2M |
| IOVA - Iovance Biotherapeutics | 1.97% | Add +0.2% | 2,116,403 | $8.02 | $17M | +3,592 | −$14M |
| Revance Therapeutics | 1.57% | Add +0.2% | 5,257,086 | $2.57 | $14M | +9,082 | −$12M |
| ALKS - Alkermes | 1.38% | Hold | 495,592 | $24.10 | $12M | — | — |
| Sage Therapeutics | 1.27% | Add +0.5% | 1,010,833 | $10.86 | $11M | +5,057 | −$8M |
| EHTH - Ehealth | 1.23% | Reduce −13.5% | 2,350,190 | $4.53 | $11M | −365,491 | −$6M |
| NVCR - Novocure | 1.12% | Hold | 561,908 | $17.13 | $10M | — | — |
| ALGN - Align Technology | 1.06% | Reduce −23.1% | 37,772 | $241.43 | $9M | −11,333 | −$7M |
| SNDX - Syndax Pharmaceuticals | 0.96% | Hold | 405,193 | $20.53 | $8M | — | — |
| Acelyrin | 0.88% | Hold | 1,715,180 | $4.41 | $8M | — | — |
| Nevro | 0.73% | Hold | 750,371 | $8.42 | $6M | — | — |
| CYTK - Cytokinetics | 0.70% | Hold | 111,717 | $54.18 | $6M | — | — |
| Gossamer Bio | 0.66% | Reduce −1.8% | 6,277,093 | $0.9009 | $6M | −114,682 | −$2M |
| Elevation Oncology | 0.56% | Add +33.7% | 1,800,106 | $2.70 | $5M | +453,440 | −$2M |
| Bluebird Bio | 0.53% | Add +1.6% | 4,633,351 | $0.9842 | $5M | +73,180 | −$1M |
| Karyopharm Therapeutics | 0.51% | Hold | 5,102,193 | $0.8676 | $4M | — | — |
| Verve Therapeutics | 0.33% | Hold | 575,817 | $4.88 | $3M | — | — |
| NUVB - Nuvation Bio | 0.26% | Hold | 772,652 | $2.92 | $2M | — | — |
| MIRM - Mirum Pharmaceuticals | 0.26% | Hold | 64,700 | $34.19 | $2M | — | — |
| RLMD - Relmada Therapeutics | 0.25% | Hold | 732,400 | $3.00 | $2M | — | — |
| TSHA - Taysha Gene Therapies | 0.21% | Hold | 811,268 | $2.24 | $2M | — | — |
| STOK - Stoke Therapeutics | 0.20% | Hold | 125,861 | $13.51 | $2M | — | — |
| HUM - Humana | 0.17% | Hold | 3,985 | $373.65 | $1M | — | — |
| TVTX - Travere Therapeutics | 0.11% | Hold | 110,719 | $8.22 | $910K | — | — |
| Vyne Therapeutics Pipe | 0.10% | Hold | 445,434 | $1.97 | $878K | — | — |
| ALDX - Aldeyra Therapeutics | 0.09% | Hold | 225,465 | $3.31 | $746K | — | — |
| ACRS - Aclaris Therapeutics | 0.07% | Hold | 569,832 | $1.10 | $627K | — | — |
| Generation Bio | 0.05% | New | 150,475 | $2.82 | $424K | +150,475 | +$424K |
| URGN - Urogen Pharma | 0.05% | Hold | 24,500 | $16.78 | $411K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2024 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| ALNY - Alnylam Pharmaceuticals | 3.08% | Exit | 0 | $149.45 | $27M | −182,766 | −$27M |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2